Cargando…

Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance

INTRODUCTION: We evaluated real-world outcomes in patients with advanced ovarian cancer (AOC) based on their cumulative risk profile and maintenance therapy (MT) status following first-line (1L) treatment. METHODS: This retrospective observational study of a nationwide electronic health record-deriv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chase, Dana, Perhanidis, Jessica, Gupta, Divya, Kalilani, Linda, Golembesky, Amanda, González-Martín, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260707/ https://www.ncbi.nlm.nih.gov/pubmed/37016186 http://dx.doi.org/10.1007/s40487-023-00227-6

Ejemplares similares

Real-world Outcomes Associated With Poly(ADP-ribose) Polymerase Inhibitor Monotherapy Maintenance in Patients With Primary Advanced Ovarian Cancer
por: Chan, John K., et al.
Publicado: (2023)

Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review
por: Chase, Dana M, et al.
Publicado: (2023)

Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
por: Bellier, Charlotte, et al.
Publicado: (2023)

Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
por: Zhao, Minmin, et al.
Publicado: (2023)

Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma Who Received Systemic Treatment
por: Park, Changhee, et al.
Publicado: (2021)

Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
por: Barretina-Ginesta, Maria-Pilar, et al.
Publicado: (2022)

Pitfalls in surveillance for hepatocellular carcinoma: How successful is it in the real world?
por: Wong, Linda L., et al.
Publicado: (2017)

Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance
por: Magnani, Christopher J., et al.
Publicado: (2020)

Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting
por: Seidenberg, André, et al.
Publicado: (2013)

Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
por: King, Gentry, et al.
Publicado: (2022)

P1204: TREATMENT PATTERNS AND REAL-WORLD OUTCOMES IN PATIENTS (PT) WITH LARGE B-CELL LYMPHOMA (LBCL) WHO RECEIVED SECOND-LINE (2L) THERAPY
por: Lunning, M., et al.
Publicado: (2022)

Probing Real Sensory Worlds of Receivers with Unsupervised Clustering
por: Pfeiffer, Michael, et al.
Publicado: (2012)

COVID-19 Vaccination Among Patients Receiving Maintenance Renal Replacement Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future
por: Rouphael, Nadine, et al.
Publicado: (2023)

Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States
por: Medhekar, Rohan, et al.
Publicado: (2022)

Ovarian Real-World International Consortium (ORWIC): A multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes
por: Cheeseman, Sue, et al.
Publicado: (2023)

Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer
por: Shoji, Tadahiro, et al.
Publicado: (2021)

Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

Real-World Safety And Effectiveness Of OnabotulinumtoxinA Treatment Of Crow’s Feet Lines And Glabellar Lines: Results Of A Korean Postmarketing Surveillance Study
por: Yi, Dong-Jin, et al.
Publicado: (2019)

Real-world use of nirmatrelvir–ritonavir: who benefits?
por: Molina, Kyle C, et al.
Publicado: (2023)

An assessment of food supplementation to chronically sick patients receiving home based care in Bangwe, Malawi : a descriptive study
por: Bowie, Cameron, et al.
Publicado: (2005)

Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen
por: Kim, Su-In, et al.
Publicado: (2022)

Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma
por: Abraham, Pranav, et al.
Publicado: (2020)

Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives
por: Reverdy, Thibaut, et al.
Publicado: (2020)

Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

Long Survival of a Small-Cell Lung Cancer Patient Who Received Maintenance Chemotherapy with Irinotecan
por: Yagi, Yoshitaka, et al.
Publicado: (2013)

Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients
por: Berton, Dominique, et al.
Publicado: (2021)

Analysis of thromboembolic events in patients with non-small cell lung cancer who received adjuvant chemotherapy: single-center real-world data
por: Kim, Tae-Hwan, et al.
Publicado: (2022)

P1747: A REAL-WORLD ANALYSIS OF HEALTHCARE RESOURCE UTILIZATION AMONG PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED TREATMENT WITH RAVULIZUMAB
por: Fishman, J., et al.
Publicado: (2022)

A Real‐World Multicentre Retrospective Study of Paclitaxel‐Bevacizumab and Maintenance Therapy as First‐Line for HER2‐Negative Metastatic Breast Cancer
por: Gamucci, Teresa, et al.
Publicado: (2016)

S-1 Maintenance Therapy After First-Line Treatment With Nab-Paclitaxel Plus S-1 for Advanced Pancreatic Adenocarcinoma: A Real-World Study
por: Shi, Yan, et al.
Publicado: (2022)

Comparative effectiveness of first-line antihypertensive drug classes on the maintenance of estimated glomerular filtration rate (eGFR) in real world primary care
por: Gao, Qiao, et al.
Publicado: (2023)

Safety and effectiveness of everolimus in maintenance kidney transplant patients in the real-world setting: results from a 2-year post-marketing surveillance study in Japan
por: Hayase, Naomi, et al.
Publicado: (2021)

Lenalidomide Maintenance and Measurable Residual Disease in a Real-World Multiple Myeloma Transplanted Population Receiving Different Treatment Strategies Guided by Access to Novel Drugs in Brazil
por: Salgado, Anna Beatriz dos Santos, et al.
Publicado: (2023)

Association between atypical endometriosis and ovarian malignancies in the real world
por: So, Kyeong A, et al.
Publicado: (2021)

Correction to: Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

528. Hospital Course of Patients Receiving Bamalanivimab: A Real World Analysis
por: Belk, Madeline, et al.
Publicado: (2021)

Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
por: Li, Jia, et al.
Publicado: (2022)

Real-World Long-Term Remission Maintenance for 10 Years With Thiopurines in Ulcerative Colitis
por: Matsumoto, Satohiro, et al.
Publicado: (2021)

Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario
por: Flores Vega, Yoanna I., et al.
Publicado: (2023)

P1182: REAL-WORLD CHARACTERISTICS AND CLINICAL OUTCOMES IN RELAPSE/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS WHO RECEIVED CAR-T THERAPY
por: Liao, L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h93ee73v2v7i0gv8p3jneg7n9u